Liminatus Pharma, Inc. (NASDAQ: LIMN) Signs MOU with Capital Trust Group for USD 30 Million Equity Investment via an earn-out mechanism and Future Strategic Cooperation
Rhea-AI Summary
Liminatus Pharma (NASDAQ: LIMN) signed a Memorandum of Understanding with Capital Trust Group for a USD 30,000,000 equity financing via an earn-out mechanism to support R&D of its immuno-oncology programs. The investment is subject to due diligence, negotiation of definitive agreements, Nasdaq and U.S. securities compliance, and effectiveness of a registration statement for resale of the shares. Both parties target execution of definitive agreements in November 2025 and plan to discuss further strategic cooperation beginning mid-November, including potential digital bond financing programs.
Positive
- USD 30.0M equity investment committed via MOU
- Planned definitive agreements targeted for November 2025
- Funding contingent on registration statement effectiveness for resale
- Agreement opens path to future strategic cooperation and digital bonds
Negative
- Investment is conditional on diligence and definitive agreements
- Subscription subject to Nasdaq and U.S. securities compliance
- Share issuance will dilute existing shareholders upon closing
News Market Reaction
On the day this news was published, LIMN declined 0.70%, reflecting a mild negative market reaction. Argus tracked a peak move of +10.4% during that session. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $324K from the company's valuation, bringing the market cap to $46M at that time.
Data tracked by StockTitan Argus on the day of publication.
LA PALMA, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (NASDAQ: LIMN), a clinical-stage immuno-oncology company developing next-generation CD47-blockade therapies, announced today that it has entered into a Memorandum of Understanding (MOU) with Capital Trust Group Limited (CTG), a New Zealand-based investment management firm, for a USD 30,000,000 equity financing via an earn-out mechanism to support Liminatus’s research and development of advanced immunotherapy assets.
Subject to completion of diligence and the negotiation of definitive agreements, CTG intends to subscribe to newly issued shares of Liminatus, subject to compliance with Nasdaq listing rules and U.S. securities laws. The subscription funds are expected to be remitted following the submission and effectiveness of a registration statement relating to the resale of the shares. Both parties aim to finalize and execute the definitive agreements in November 2025.
In addition to the equity investment, beginning in mid-November this year and subject to definitive agreements being signed, Liminatus and CTG plan to commence discussions for further strategic cooperation, including potential future digital bond financing programs.
“We believe that this MOU marks the beginning of a long-term partnership with CTG,” said Chris Kim, Chief Executive Officer of Liminatus Pharma. “The equity financing would strengthen our financial foundation.”
About Liminatus Pharma, Inc. (NASDAQ: LIMN)
Liminatus Pharma is a clinical-stage immuno-oncology company pioneering next-generation therapeutics, including its proprietary CD47-blockade antibody IBA101, designed to overcome the limitations of first-generation immune therapies in solid tumors.
About Capital Trust Group Limited (CTG)
Capital Trust Group is a New Zealand-based investment management and digital finance firm managing large-scale institutional and blockchain-enabled financing programs across healthcare, energy, and infrastructure sectors. CTG has the privilege of having General Chavalit Yongchaiyudh, the 22nd Prime Minister of Thailand, as one of its shareholders and an honorable advisor.
Contacts
Liminatus Pharma, Inc.:
Chris Kim, CEO — info@liminatuspharma.com, (213) 273-5453
Capital Trust Group:
Wasupit Wises, Director — wises@ctgprime.com, +66 61 7722142
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the expected equity investment, timing of definitive agreements, potential future digital bond programs, and anticipated financial and strategic benefits. These statements are based on current expectations and involve risks and uncertainties that could cause actual results to differ materially from those described herein. Factors that may cause such differences include, among others, the ability to finalize and execute definitive agreements, regulatory and market conditions, and the availability of financing. Liminatus undertakes no obligation to update or revise any forward-looking statements, except as required by law.
FAQ
What did Liminatus (LIMN) announce on October 30, 2025 regarding financing?
When do Liminatus and Capital Trust Group expect to finalize definitive agreements for the LIMN investment?
What conditions must be met before Capital Trust Group remits the USD 30M to LIMN?
Will the USD 30M financing for LIMN immediately affect outstanding shares?
Does the LIMN MOU include additional cooperation beyond the equity investment?
